Proactive Investors - Run By Investors For Investors

Genus upgraded to ‘buy’ by Peel Hunt after share placing

The placing proceeds will ensure balance sheet flexibility to continue to invest in the business and to take advantage of infill acquisition opportunities, Peel Hunt analysts said
Genus upgraded to ‘buy’ by Peel Hunt after share placing
Peel Hunt said the current share price was an attractive entry point into a high quality business

Genus PLC (LON:GNS) was upgraded to a ‘buy’ from a ‘hold’ rating by broker Peel Hunt after the animal genetics company said on Friday it had raised of £68mln through a share placing.

Genus said 3.1mln new shares were issued to new and existing investors at a price of 2,200p per placing share.

READ: Genus raises of £68mln through share placing

“The proceeds will ensure balance sheet flexibility to continue to invest in the business and to take advantage of infill acquisition opportunities,” Peel Hunt analysts wrote in a note to clients.

“The raise is slightly dilutive (c3% in the short term) but should be materially accretive as the company strengthens its strategic position and breeding capacity.”

Genus’s share price is 25% off the peak it reached last July, triggered by the outbreak of African swine fever (ASF) in China.

Peel Hunt said the current share price was an attractive entry point into a high-quality business with attractive long-term growth potential combined with the transformative opportunity in gene editing. Peel Hunt maintained its 2,600p target price.

Genus was earlier this week upgraded to a ‘buy’ from a ‘hold’ rating by broker Kepler Chevreux who believes the fall in the animal genetics company’s share price on the back of fears over the outbreak of African swine fever has been overdone.

Genus shares were 5.6% down at 2,258.0p in mid-morning trade.

View full GNS profile View Profile

Genus Timeline

Newswire
February 16 2015

Related Articles

A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use